Versartis to Hold Conference Call to Discuss VRS-317

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Versartis to Hold Conference Call to Discuss VRS-317 Clinical Update From Ongoing Extension Study

MENLO PARK, Calif., Dec. 29, 2014 (GLOBE NEWSWIRE) -- Versartis, Inc. (Nasdaq: VSAR ), an endocrine-focused biopharmaceutical company developing a novel, long-acting form of recombinant human growth hormone (rhGH) for the treatment of growth hormone deficiency (GHD), today announced it will hold a conference call and webcast on Monday, January 5, 2015 at 8:30 a.m. ET (5:30 a.m. PT).

During the call, Versartis management will provide a safety and efficacy update on pediatric GHD patients currently enrolled in its ongoing long-term Extension Study with VRS-317. Pediatric patients completing the Phase 2a VERTICAL trial were offered the opportunity to continue therapy in the Extension Study and approximately 95% of the Phase 2a patients elected to participate. The Extension Study clinical update will also be announced in a press release prior to the call.

Conference Call and Webcast

Versartis will hold a conference call on Monday, January 5, 2015 at 8:30 a.m. ET (5:30 a.m. PT). The dial-in numbers are (877) 407-0789 for domestic callers and (201) 689-8562 for international callers. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.versartis.com .

After the live webcast, a replay will remain available on the Versartis website, www.versartis.com , for 90 days. In addition, a telephonic replay of the call will be available until January 19, 2015. The replay dial-in numbers are (877) 870-5176 for domestic callers and (858) 384-5517 for international callers. Please use the replay conference ID number 13598346.

The VRS-317 VERTICAL Study     

The Ver sartis T rial I n C hildren to A ssess L ong-Acting Growth Hormone (VERTICAL) study was conducted in approximately 25 US pediatric endocrinology centers and enrolled 64 treatment-naive, pre-pubertal children with GHD documented by auxologic criteria and two growth hormone (GH) stimulation tests.

The VERTICAL trial consisted of two stages: a single ascending dose stage (Phase 1b) to determine the safety, PK and PD of VRS-317 doses and to enable selection of dose regimens, which were then used in the repeat-dose second stage (Phase 2a).

The primary endpoint of the Phase 2a study was mean 6-month height velocity. Based on observed PK/PD results, 64 subjects were enrolled in the Phase 2a stage and randomized into three cohorts to evaluate three different dosing regimens of VRS-317: 5.0 mg/kg monthly, 2.5 mg/kg semi-monthly or 1.15 mg/kg weekly. At the start of repeat dosing, the subjects (37M/27F) had a mean (SD) age of 7.8 (2.4) years, HT-SDS of -2.5 (0.5) and IGF-I SDS of -1.7 (0.8).

Results from the completed Phase 2a stage of the VERTICAL study were first reported on June 23, 2014 at the 16 th International Congress of Endocrinology and The Endocrine Society's 96 th Annual Meeting and Expo (ICE/ENDO) in Chicago, IL and announced in the following press release: http://ir.versartis.com/releasedetail.cfm?ReleaseID=856043

As disclosed on its third quarter 2014 financial results conference call, Versartis expects to begin enrollment of its Phase 3 VELOCITY Study of VRS-317 in early 2015.

The VRS-317 Phase 3 VELOCITY Study

The Ver sartis Lo ng-Acting Growth Hormone in C h i ldren compared T o Dail y rhGH (VELOCITY Study) is a randomized, open-label, Phase 3 registration study in the United States, Western Europe and Canada. This study will enroll up to 136 treatment-naïve, pre-pubertal children with GHD and will include a 3:1 randomization of 3.5 mg/kg VRS-317 semi-monthly to daily rhGH at the highest labeled dose of Genotropin ® (somatropin [rDNA origin] for injection) and Norditropin ® (somatropin [rDNA origin] for injection) 34 µg/kg/day. The primary endpoint is non-inferiority between the two treatment groups for 12 month height velocity. GHD patients enrolling in this study will also be offered the opportunity to enroll in the ongoing Extension Study. 

About Versartis

Versartis, Inc. is an endocrine-focused biopharmaceutical company initially developing VRS-317, a novel, long-acting form of recombinant human growth hormone, for the treatment of growth hormone deficiency (GHD). VRS-317 is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance and adherence and, therefore, treatment outcomes. The Company completed a Phase 2a clinical trial evaluating weekly, semi-monthly and monthly dosing regimens of VRS-317 in children with GHD in June, 2014 and is initiating a Phase 3 study in the same patient population in early 2015. Further information on Versartis can be found at www.versartis.com .

Cautionary Note on Forward Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "expects" "intend," "potential," "will" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: plans regarding our anticipated Phase 3 VELOCITY study and potential benefits of and market opportunity for VRS-317. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: our success being heavily dependent on VRS-317; VRS-317 being a new chemical entity; serious adverse side effects, if they are associated with VRS-317; VRS-317 may not have favorable results in later clinical trials or receive regulatory approval; other long-acting rhGH products and product candidates have failed to generate commercial success or obtain regulatory approval; delays in enrollment of patients in our clinical trials could increase our costs and cause delay; VRS-317 may cause serious adverse side effects or have properties that delay or prevent regulatory approval or limit its commercial profile; manufacturing; if approved, risks associated with market acceptance, including pricing and reimbursement; our ability to enforce our intellectual property rights; the importance of our license of intellectual property from Amunix Operating, Inc. and our need for additional funds to support our operations. We discuss many of these risks in greater detail under the heading "Risk Factors" section contained in our Quarterly Report on Form 10-Q for the 3 months ended September 30, 2014, which is on file with the Securities and Exchange Commission (SEC). Forward-looking statements are not guarantees of future performance and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Corporate Joshua Brumm Chief Financial Officer (650) 963-8582 Investors Nick Laudico The Ruth Group (646) 536-7030 Media Debra Bannister Corporate Communications (530) 676-7373

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dr. Kumar Joins Florida Cancer Specialists Team

Updated Category News Views 152

Welcoming a New Oncology Specialist to Bradenton What does a small but mighty addition mean for cancer care in Bradenton, Florida? Well, it feels like a big win for the locals. Dr. Vinod Kumar is the latest name to join the ranks of the Florida Cancer Specialists & Research Institute (FCS) at the Bradenton Cancer Center. With years under his belt in medical oncology and...

Continue Reading
Cargo Drones to Skyrocket with $9.14B Value by 2031

Updated Category News Views 121

Riding the Drone Wave I tell you what, folks, the whole business of cargo drones is getting frickin' interesting. These flying gizmos, once dismissed as science fiction, are now barging their way into logistics discussions like an uninvited guest who's too worthwhile to ignore. MarketsandMarkets™ reckons this market's about to smash through the $9 billion ceiling by...

Continue Reading
Ross Pools Joins Forces with Florida Panthers in 2026

Updated Category News Views 28

An Unlikely Team-Up: Pools and Hockey Well, here's one for the books: a South Florida pool company hitching its wagon to an NHL team. Ross Pools, the folks who’ve been carving out backyard oases in the sizzling Florida sun for over two decades, are now officially aligned with the Florida Panthers. Yeah, the same Panthers that snatched the Stanley Cup not once but twice...

Continue Reading
Keiki Smiles Boosts Pediatric Dental Care in Waipahu

Updated Category News Views 83

A Neighborhood Dentists' Big Move: Keiki Smiles Expands in Waipahu Well, if there's one thing the dentists of Waipahu know how to do, it's adapt and grow. Keiki Smiles of Leeward, a trusted name in pediatric dentistry, just set up shop at a fresh location. The move marks a new chapter for this community staple, and honestly, it's miles more than just a longer lease and a...

Continue Reading
Sabre Unveils AI Travel Tech: A Bold New Frontier

Updated Category News Views 30

Sabre's Game-Changing AI Travel Integration I'm no stranger to bold moves in the travel industry, but what Sabre's rolling out tomorrow might just be the biggest leap we've seen in a while. They're unleashing what's called the first global travel plug-in within Grok Bot, marking a significant shake-up in the travel tech sphere. Too many tech upgrades in this business...

Continue Reading
NeuroPace Faces Investigation After Revenue Forecast Cut

Updated Category News Views 35

NeuroPace Revenue Drama: A Blow to Investor Confidence How the mighty have stumbled—or so it feels to the folks who put their bucks into NeuroPace, Inc. (NASDAQ: NPCE). It's tough to swallow: they cut their 2026 revenue forecast from a hopeful $99.5-$101.5 million to a sobering $91-$92 million. Just one quarter apart those projections are, like a cruel twist of fate...

Continue Reading
Caregiving's Financial Impact on Women: Insights from Cinergy

Updated Category News Views 106

Women Caregivers Face Financial Crossroads When it comes down to it, caregiving is one heck of a responsibility, particularly for women. It's about the sacrifices they make, not just in time but in financial security, too. Step away from a job to care for someone, and it's a dicey game you're playing with future income. The Cost of Generosity: Financial Impacts Cindy...

Continue Reading
Norris Lake's New Kayak Fleet Propels Tourism Efforts

Updated Category News Views 22

Norris Lake Doubles Down on Water Adventures The winds of change are paddling through Norris Dam State Park as they've launched a new fleet of shiny kayaks, hoping to lure more adventure seekers into the heart of Tennessee. These ain't just boats; they're part of a bigger play by local tourism honchos hungry to pump some adrenaline—and dollars—back into the area. A...

Continue Reading
NVIDIA Faces Turbulent Storm with CEO Resignation

Updated Category News Views 81

Huang's Unexpected Exit and NVIDIA's Rocky Road Well, talk about drama in Silicon Valley. When executives start stumbling, it's not just some PR nightmare—it's a full-on crisis. NVIDIA's co-founder and CEO Jensen Huang is calling it quits, and not on some smooth, idyllic note. No, this is the kind of exit that investors dread. You’ve got affairs, security concerns,...

Continue Reading
Christian Faith: Navigating Spiritual Pitfalls Wisely

Updated Category News Views 111

Taking a Deep Look at Christian Faith If you think faith is as simple as saying a few prayers and checking church attendance off the list, well, think again. G. Joseph Johnson, in his thought-provoking tome "Roads, Ditches, Traps, and Snares," believes that faith is a journey filled with twists, turns, and yes, a few traps. This book is a sort of roadmap for Christians,...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Launched for SelectQuote, Inc. Shareholders

Updated Category News Views 231

Rosen Law Firm Investigates SelectQuote, Inc. Securities Claims The Rosen Law Firm has recently announced an investigation focusing on SelectQuote, Inc. (NYSE: SLQT) due to potential securities claims that may affect shareholders. The firm is dedicated to upholding investor rights and protecting shareholders from misleading information that might influence stock...

Continue Reading
Indonesia's IDX Composite Index Experiences Minor Decline

Updated Category News Views 239

Well, let’s cut to the chase. Indonesia's stock market is feeling a bit queasy lately. The IDX Composite Index slipped by 0.18%, taking a hit thanks to major sectors like Financials, Infrastructure, and Agriculture showing significant losses. This isn’t just some random shuffle; these sectors often serve as economic bellwethers that reflect broader trends in the...

Continue Reading
Trade Tensions Impact Qualcomm Stock Performance Today

Updated Category News Views 126

Trade Tensions Impact Qualcomm Shares Qualcomm Inc (NASDAQ: QCOM) is experiencing a decline in its share price, attributed to rising trade tensions. Reports indicate that the U.S. government is preparing to implement restrictions on AI chip shipments to certain Southeast Asian countries, primarily Malaysia and Thailand, due to ongoing concerns regarding China. New Export...

Continue Reading
Historic $100 Million Donation to Improve Pediatric Mental Health

Updated Category News Views 184

Transforming Pediatric Behavioral Health BOSTON — A groundbreaking gift of $100 million from Rob and Karen Hale has been announced by Boston Children's Hospital. This donation marks the largest in the hospital's storied history and is set to revolutionize pediatric behavioral health care. The Hale family's incredible generosity is aimed at reimagining how mental and...

Continue Reading
Mark Carney Takes Charge: Canada's Bold Steps to Trade Victory

Updated Category News Views 414

Mark Carney: Canada's New Prime Minister Mark Carney has emerged victorious in the leadership race of the Liberal Party, succeeding Justin Trudeau as Canada’s prime minister. With a commanding win, he pledged to confront U.S. President Donald Trump head-on, especially regarding increasing trade tensions. A Strong Start in Leadership In a remarkable demonstration of...

Continue Reading